These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15492770)

  • 1. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.
    Nordlander M; Sjöquist PO; Ericsson H; Rydén L
    Cardiovasc Drug Rev; 2004; 22(3):227-50. PubMed ID: 15492770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clevidipine: a review of its use in the management of acute hypertension.
    Deeks ED; Keating GM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clevidipine for the treatment of severe hypertension in adults.
    Nguyen HM; Ma K; Pham DQ
    Clin Ther; 2010 Jan; 32(1):11-23. PubMed ID: 20171407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery.
    Kieler-Jensen N; Jolin-Mellgård A; Nordlander M; Ricksten SE
    Acta Anaesthesiol Scand; 2000 Feb; 44(2):186-93. PubMed ID: 10695913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clevidipine in adult cardiac surgical patients: a dose-finding study.
    Bailey JM; Lu W; Levy JH; Ramsay JG; Shore-Lesserson L; Prielipp RC; Brister NW; Roach GW; Jolin-Mellgard A; Nordlander M
    Anesthesiology; 2002 May; 96(5):1086-94. PubMed ID: 11981147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension.
    Kenyon KW
    Ann Pharmacother; 2009 Jul; 43(7):1258-65. PubMed ID: 19584385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1.
    Levy JH; Mancao MY; Gitter R; Kereiakes DJ; Grigore AM; Aronson S; Newman MF
    Anesth Analg; 2007 Oct; 105(4):918-25, table of contents. PubMed ID: 17898366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashort-acting calcium antagonist clevidipine.
    Segawa D; Sjöquist PO; Wang QD; Gonon A; Nordlander M; Rydén L
    J Cardiovasc Pharmacol; 2000 Sep; 36(3):338-43. PubMed ID: 10975591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II.
    Segawa D; Sjöquist PO; Wang QD; Gonon A; Rydén L
    J Cardiovasc Pharmacol; 2002 Sep; 40(3):339-45. PubMed ID: 12198319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs.
    Ericsson H; Tholander B; Björkman JA; Nordlander M; Regårdh CG
    Drug Metab Dispos; 1999 May; 27(5):558-64. PubMed ID: 10220482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.
    Ericsson H; Fakt C; Jolin-Mellgård A; Nordlander M; Sohtell L; Sunzel M; Regårdh CG
    Br J Clin Pharmacol; 1999 May; 47(5):531-8. PubMed ID: 10336577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative Use of Clevidipine: A Systematic Review and Meta-Analysis.
    Espinosa A; Ripollés-Melchor J; Casans-Francés R; Abad-Gurumeta A; Bergese SD; Zuleta-Alarcon A; López-Timoneda F; Calvo-Vecino JM;
    PLoS One; 2016; 11(3):e0150625. PubMed ID: 27018586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers.
    Ericsson H; Bredberg U; Eriksson U; Jolin-Mellgård A; Nordlander M; Regårdh CG
    Anesthesiology; 2000 Apr; 92(4):993-1001. PubMed ID: 10754618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug evaluation of clevidipine for acute hypertension.
    Noviawaty I; Uzun G; Qureshi AI
    Expert Opin Pharmacother; 2008 Oct; 9(14):2519-29. PubMed ID: 18778189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients.
    Aronson S; Dyke CM; Stierer KA; Levy JH; Cheung AT; Lumb PD; Kereiakes DJ; Newman MF
    Anesth Analg; 2008 Oct; 107(4):1110-21. PubMed ID: 18806012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension.
    Smith WB; Marbury TC; Komjathy SF; Sumeray MS; Williams GC; Hu MY; Mould DR
    Eur J Clin Pharmacol; 2012 Oct; 68(10):1385-94. PubMed ID: 22457015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+ channel blocker.
    Gradman AH; Vivas Y
    Expert Opin Investig Drugs; 2007 Sep; 16(9):1449-57. PubMed ID: 17714030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide.
    Gourine AV; Pernow J; Poputnikov DM; Sjöquist PO
    J Cardiovasc Pharmacol; 2002 Oct; 40(4):564-70. PubMed ID: 12352318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials.
    Aronson S
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):465-72. PubMed ID: 19419254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I.
    Wang QD; Segawa D; Ericsson H; Sjöquist PO; Johansson L; Rydén L
    J Cardiovasc Pharmacol; 2002 Aug; 40(2):228-34. PubMed ID: 12131552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.